Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Molar pregnancy mystery: to treat or not to treat lung nodules?

NCT ID NCT03785574

Knowledge-focused Sponsor: Women's Hospital School Of Medicine Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the best way to manage women who have a molar pregnancy (a rare abnormal pregnancy) and also have a lung nodule found on a CT scan. Researchers want to see if starting chemotherapy right away is better than waiting to see if the nodule goes away on its own. About 30 participants will be randomly assigned to either immediate treatment or close monitoring to track outcomes like how many chemotherapy cycles are needed and whether the nodule shrinks without treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2018

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria Eligible patients have to meet all of the following criteria: 1. Pathologically confirmed HM. 2. The lung nodules are detected by lung CT and metastatic lesions could not be excluded (before or after the suction dilation and curettage). 3. The hCG level does not meet FIGO diagnostic criteria (2018) of GTN. 4. The patients are willing to compliant with the study protocol and be followed up at regular intervals. 5. The patients agree to sign an informed consent form. Exclusion criteria 1. The patients with a previous history of lung nodules. 2. The imaging impression of lung nodules suggested definitely caused by other diseases, such as tuberculosis, pneumonia, etc. 3. The patients have undergone prophylactic hysterectomy or chemotherapy. 4. Pathologically confirmed gestational trophoblastic neoplasia before and at enrollment. 5. Patients have immunosuppressive diseases or take immunosuppressants. 6. Patients are participating in other clinical trials at same time. 7. Patients were unable or unwilling to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gestational trophoblastic neoplasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Gestational Trophoblastic Disease gestational trophoblastic neoplasm hydatidiform mole

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gestational trophoblastic neoplasia Hydatidiform mole

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Weiguo Lv

    RECRUITING

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.